Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $239.00

Revolution Medicines (NASDAQ:RVMD) had its target price lifted by Truist Financial from $231.00 to $239.00 in a research report sent to investors on Thursday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

RVMD has been the subject of a number of other research reports. Wolfe Research reissued an “outperform” rating and set a $220.00 target price on shares of Revolution Medicines in a research note on Monday, August 10th. Needham & Company LLC raised their price target on shares of Revolution Medicines from $236.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Guggenheim lifted their price objective on Revolution Medicines from $235.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. TD Cowen upgraded Revolution Medicines to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Mizuho increased their target price on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Revolution Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $198.89.

Revolution Medicines Price Performance

Revolution Medicines stock opened at $207.88 on Thursday. The stock has a market capitalization of $44.56 billion, a P/E ratio of -23.57 and a beta of 1.39. The company’s fifty day moving average price is $193.33 and its 200 day moving average price is $148.59. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. Revolution Medicines has a 1 year low of $37.56 and a 1 year high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the prior year, the business posted ($1.31) EPS. As a group, equities research analysts anticipate that Revolution Medicines will post -8.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Revolution Medicines news, insider Stephen Michael Kelsey sold 4,175 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total value of $651,801.00. Following the transaction, the insider directly owned 291,876 shares of the company’s stock, valued at $45,567,681.12. This trade represents a 1.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret A. Horn sold 60,400 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $160.17, for a total value of $9,674,268.00. Following the transaction, the chief operating officer owned 158,222 shares in the company, valued at approximately $25,342,417.74. This represents a 27.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 212,497 shares of company stock worth $38,206,486. 7.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Revolution Medicines

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Contravisory Investment Management Inc. acquired a new stake in shares of Revolution Medicines in the 2nd quarter worth $32,000. Global Retirement Partners LLC raised its holdings in shares of Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after acquiring an additional 361 shares during the period. Torren Management LLC acquired a new position in shares of Revolution Medicines during the 4th quarter valued at about $33,000. Johnson Financial Group Inc. acquired a new position in shares of Revolution Medicines during the 2nd quarter valued at about $37,000. Finally, Arax Advisory Partners purchased a new stake in shares of Revolution Medicines in the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.